Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1832 1
1843 1
1859 2
1868 1
1889 1
1923 1
1925 1
1929 1
1947 1
1948 1
1949 1
1950 1
1951 7
1952 5
1953 2
1955 1
1956 2
1957 1
1960 1
1961 3
1962 3
1963 1
1964 7
1965 5
1966 11
1967 10
1968 4
1969 11
1970 5
1971 13
1972 14
1973 11
1974 14
1975 17
1976 13
1977 21
1978 11
1979 22
1980 22
1981 11
1982 16
1983 10
1984 10
1985 17
1986 23
1987 21
1988 29
1989 30
1990 31
1991 33
1992 17
1993 28
1994 33
1995 32
1996 30
1997 27
1998 29
1999 35
2000 40
2001 33
2002 44
2003 45
2004 59
2005 70
2006 72
2007 77
2008 91
2009 109
2010 112
2011 102
2012 118
2013 134
2014 150
2015 145
2016 147
2017 164
2018 155
2019 146
2020 160
2021 157
2022 133
2023 139
2024 124
2025 142
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,268 results

Results by year

Filters applied: . Clear all
Page 1
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: shaw at. J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31. J Clin Oncol. 2024. PMID: 38819031 Free PMC article. Clinical Trial.
ALK-positive lung cancer: a moving target.
Schneider JL, Lin JJ, Shaw AT. Schneider JL, et al. Among authors: shaw at. Nat Cancer. 2023 Mar;4(3):330-343. doi: 10.1038/s43018-023-00515-0. Epub 2023 Feb 16. Nat Cancer. 2023. PMID: 36797503 Free PMC article. Review.
Fluids in the ICU: which is the right one?
Mayerhöfer T, Shaw AD, Wiedermann CJ, Joannidis M. Mayerhöfer T, et al. Among authors: shaw ad. Nephrol Dial Transplant. 2023 Jun 30;38(7):1603-1612. doi: 10.1093/ndt/gfac279. Nephrol Dial Transplant. 2023. PMID: 36170962 Free PMC article. Review.
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, Riley A, Lawlor M, Banwait MK, Cobb RG, Zou L, Dyson NJ, Ott CJ, Benes C, Getz G, Chan CS, Shaw AT, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Yeap BY, Engelman JA, Lee JJ, Maruvka YE, Buisson R, Lawrence MS, Hata AN. Isozaki H, et al. Among authors: shaw at. Nature. 2023 Aug;620(7973):393-401. doi: 10.1038/s41586-023-06303-1. Epub 2023 Jul 5. Nature. 2023. PMID: 37407818 Free PMC article.
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Ravi A, et al. Among authors: shaw at. Nat Genet. 2023 May;55(5):807-819. doi: 10.1038/s41588-023-01355-5. Epub 2023 Apr 6. Nat Genet. 2023. PMID: 37024582 Free PMC article.
Management of oliguria.
Ostermann M, Shaw AD, Joannidis M. Ostermann M, et al. Among authors: shaw ad. Intensive Care Med. 2023 Jan;49(1):103-106. doi: 10.1007/s00134-022-06909-5. Epub 2022 Oct 20. Intensive Care Med. 2023. PMID: 36266588 No abstract available.
Response and Resistance to RAS Inhibition in Cancer.
Ebright RY, Dilly J, Shaw AT, Aguirre AJ. Ebright RY, et al. Among authors: shaw at. Cancer Discov. 2025 Jul 3;15(7):1325-1349. doi: 10.1158/2159-8290.CD-25-0349. Cancer Discov. 2025. PMID: 40293709 Review.
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: shaw at. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
Induction of a distinct macrophage population and protection from lung injury and fibrosis by Notch2 blockade.
Cruz Tleugabulova M, Melo SP, Wong A, Arlantico A, Liu M, Webster JD, Lau J, Lechner A, Corak B, Hodgins JJ, Garlapati VS, De Simone M, Korin B, Avraham S, Lund J, Jeet S, Reiss A, Bender H, Austin CD, Darmanis S, Modrusan Z, Brightbill H, Durinck S, Diamond MS, Schneider C, Shaw AS, Nitschké M. Cruz Tleugabulova M, et al. Among authors: shaw as. Nat Commun. 2024 Nov 6;15(1):9575. doi: 10.1038/s41467-024-53700-9. Nat Commun. 2024. PMID: 39505846 Free PMC article.
3,268 results